||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
IS Pharma Share Discussion Threads
Showing 351 to 372 of 375 messages
|Looks like they were short of cash as this product was selling well, with great long term profit potential!|
|THIS WAS INDEED A BAD DEAL FOR SHARE HOLDERS¬!|
|This deal does not look so good for the old maleor holders :@7p|
|Been out of it for a while chaps what happened to ISPH WAS IT A GOOD DEAL FOR SHAREHOLDERS?|
|Looks like merger will conclude 23/5/11 (end ISPH) listing
Director buying SPH at 36p
Topped up 5000 ISPH also, seem good value against SPH sp|
|After merger deals it always takes time to settle down, but for SPH holders it seems an easy move to sell SPH and buy ISPH until the differential disappears ..|
|why the discount to the deal price? I understand that the price is linked to the SPH price but surely it should move accordingly and only have a small discount?
Seems like a 'money for nothing'opportunity to still buy?|
|Merger agreed 99.1 per share.|
|Still no news on merger, but SPH still generating news :
London, UK, and Singapore, March 21, 2011 - Sinclair Pharma Plc ("Sinclair" or "the Company": SPH:L), the international specialty pharmaceutical company and Invida Holdings Private Limited ("Invida") are pleased to announce the inclusion of India into their long-term partnership for the commercialisation of Sinclair's market leading dermatology brands in the Asia Pacific region. Invida is the region's leading specialty biopharmaceutical company with 4,000 employees and a presence in all major markets, including India.|
|Thanks Red Ninja.
Makes for some interesting reading.|
|Sinclair Pharma cuts first-half loss
24/02/2011 Robert Tyerman
Merger candidate Sinclair Pharma (SPH) has slashed interim losses 73 per cent to £3.6 million, helped by new product launches and acquisitions. The fully-listed company, steered by entrepreneurial chief executive officer Chris Spooner, increased turnover 28 per cent to £14.1 million in the six months to December and cut net debt from £15.2 million to £2.4 million.
Sinclair, which specialises in oral health, dermatology and wound care and is still discussing a possible merger with AIM counter IS Pharma, expanded in the first half by buying wound care products Flammazine and Flammacerium from Belgium's Solvay Group, helped by a £19 million funding at 28p in October. The company bought European licensing rights to US group Advanced Bio Technologies' Kelo-Cote scar reduction formulation and launched its Atopiclair eczema and dermatitis cream in France and Spooner says first Asian product launches are expected in the middle of this year.
Highlighted by Growth Company Investor at 28p last autumn, Sinclair shares now trade at 37p, valuing the company at £86 million. Hold on.|
|Worth 99p at the moment; looking at ISPH eps forecasts, merger should fail.|
|2.6868 Sinclair per IS Pharma is worth 106p with Sinclair at 39.5p offered.
Strangely odd discount.I would have thought that IS Pharma should be trading around 98-100p level.Presuming Sinclair /ISP market their intentions effectivly,there's nice upside here.|
|Mmm It could be a good deal for both companies.
Many VCT's have holdings in IS Pharma, will they have to sell due to the new company being much larger ?|
|Very good and a merger has arrived.Prophetic words.
So Mr Wright with Mr Spooner.Could be a powerful combination.Industry expertise and Mr Spooners obvious financial acumen.
SPH have a full LSE quote that i like.|
|One thing that strikes me is that with IS Pharma focused in Europe and Helsinn focused in the US and the fact they are licensing each other products well I wouldn't be suprised if there was a future merger .....|
|An interesting start to the year...
A flurry of interest on the back of the article, which is always nice.|
|A nice tip of the hat from Citywire...
|Having seen some disastrous investment decisions elsewhere by Blackrock I can't say their choices are faultless, but hopefully here they won't have any cause to regret their ISPH investment. Nevertheless it's nice to have an expanding institutional investor base from purchases at reasonably fair prices.|
|Blackrock love us too. How things have changed for ISPH...|
|Mmm, and now BlackRock are increasing their stake too...